Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 02/27/24
Arcutis to Present at the Guggenheim Healthcare Talks – 6th Annual Biotechnology ConferenceGlobeNewsWire • 01/31/24
Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 TrialGlobeNewsWire • 01/29/24
ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United StatesGlobeNewsWire • 01/22/24
Arcutis Biotherapeutics, Inc. (ARQT) Moves to Strong Buy: Rationale Behind the UpgradeZacks Investment Research • 01/18/24
ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical SteroidsGlobeNewsWire • 01/14/24
Majority of Individuals with Atopic Dermatitis Improved with Arcutis' Roflumilast Cream 0.15% According to New Data from Phase 3 ProgramGlobeNewsWire • 01/14/24
FDA Approves Arcutis' ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and OlderGlobeNewsWire • 12/15/23
FDA Accepts Arcutis' Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6GlobeNewsWire • 11/29/23
After Plunging -35.64% in 4 Weeks, Here's Why the Trend Might Reverse for Arcutis Biotherapeutics, Inc. (ARQT)Zacks Investment Research • 11/17/23
Top 5 Health Care Stocks That Are Preparing To Pump In November - Better Therapeutics (NASDAQ:BTTX), Arcutis Biotherapeutics (NASDAQ:ARQT)Benzinga • 11/03/23
Arcutis Announces Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 11/03/23
Down -50.77% in 4 Weeks, Here's Why You Should You Buy the Dip in Arcutis Biotherapeutics, Inc. (ARQT)Zacks Investment Research • 11/01/23
Arcutis Biotherapeutics, Inc. (ARQT) Loses -51.27% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 10/31/23